Get the Stockscreener App
2.56
1.59%
0.04
After Hours:
2.70
0.14
+5.47%
Aclaris Therapeutics Inc stock is traded at $2.56, with a volume of 1.24M.
It is up +1.59% in the last 24 hours and up +37.63% over the past month.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
See More
Previous Close:
$2.52
Open:
$2.65
24h Volume:
1.24M
Relative Volume:
1.19
Market Cap:
$277.33M
Revenue:
$27.08M
Net Income/Loss:
$-37.00M
P/E Ratio:
-4.9231
EPS:
-0.52
Net Cash Flow:
$-18.46M
1W Performance:
+9.40%
1M Performance:
+37.63%
6M Performance:
+77.78%
1Y Performance:
+22.49%
1-Day Range:
$2.40
$2.70
1-Week Range:
$2.24
$2.70
52-Week Range:
$1.05
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Name
Aclaris Therapeutics Inc
Sector
Industry
Phone
484-324-7933
Address
701 LEE ROAD, WAYNE, PA
Compare ACRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
2.56 | 273.00M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Piper Sandler | Overweight |
| May-28-25 | Initiated | Wedbush | Outperform |
| Mar-18-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-23-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-19-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-19-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-18-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-22-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-03-23 | Initiated | Evercore ISI | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Oct-06-22 | Initiated | BTIG Research | Buy |
| Jul-23-21 | Resumed | Jefferies | Buy |
| Jun-15-21 | Initiated | Piper Sandler | Overweight |
| Apr-21-21 | Initiated | H.C. Wainwright | Buy |
| Oct-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-06-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-27-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-06-19 | Initiated | SVB Leerink | Outperform |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Feb-09-18 | Initiated | Guggenheim | Buy |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-29-16 | Initiated | Leerink Partners | Outperform |
| Sep-30-16 | Initiated | JMP Securities | Mkt Outperform |
| Jun-10-16 | Initiated | Guggenheim | Buy |
| Nov-02-15 | Initiated | Citigroup | Buy |
| Nov-02-15 | Initiated | Jefferies | Buy |
View All
Aclaris Therapeutics Inc Stock (ACRS) Latest News
Will Aclaris Therapeutics Inc. stock outperform international peersTrade Ideas & Risk Managed Investment Entry Signals - newser.com
Key resistance and support levels for Aclaris Therapeutics Inc.2025 Geopolitical Influence & Free Technical Pattern Based Buy Signals - newser.com
Understanding Aclaris Therapeutics Inc.’s price movement2025 Top Gainers & High Yield Stock Recommendations - newser.com
Risk adjusted return profile for Aclaris Therapeutics Inc. analyzedWeekly Stock Report & Daily Profit Maximizing Tips - newser.com
Applying chart zones and confluence areas to Aclaris Therapeutics Inc.Dollar Strength & AI Enhanced Execution Alerts - newser.com
Will Aclaris Therapeutics Inc. stock deliver shareholder valueJuly 2025 Weekly Recap & Fast Gain Stock Trading Tips - newser.com
Can Aclaris Therapeutics Inc. stock deliver strong Q4 earningsJuly 2025 Selloffs & AI Enhanced Trading Alerts - newser.com
Statistical indicators supporting Aclaris Therapeutics Inc.’s strengthWatch List & Long Hold Capital Preservation Plans - newser.com
Why Aclaris Therapeutics Inc. (8AT) stock is a must watch tickerPortfolio Update Summary & AI Forecasted Stock Moves - newser.com
Why Aclaris Therapeutics Inc. (8AT) stock gets analyst attentionPortfolio Update Report & Proven Capital Preservation Methods - newser.com
Will Aclaris Therapeutics Inc. (8AT) stock hit Wall Street targetsWeekly Profit Report & Fast Moving Stock Watchlists - newser.com
How Aclaris Therapeutics Inc. (8AT) stock performs during market turbulenceJuly 2025 News Drivers & Fast Entry Momentum Alerts - newser.com
Will Aclaris Therapeutics Inc. benefit from macro trendsIndex Update & Stock Portfolio Risk Management - newser.com
Using Python tools to backtest Aclaris Therapeutics Inc. strategiesJuly 2025 Analyst Calls & AI Enhanced Trading Signals - newser.com
Why Aclaris Therapeutics Inc. stock attracts global investorsMarket Sentiment Review & Verified Momentum Watchlists - newser.com
Can you recover from losses in Aclaris Therapeutics Inc.Rate Cut & Safe Capital Growth Stock Tips - newser.com
Aclaris Therapeutics (NASDAQ:ACRS) adds US$40m to market cap in the past 7 days, though investors from three years ago are still down 83% - Yahoo Finance
How Aclaris Therapeutics Inc. stock trades before earningsWeekly Profit Report & Daily Stock Momentum Reports - newser.com
Is Aclaris Therapeutics Inc. stock a contrarian buy2025 Valuation Update & Fast Exit Strategy with Risk Control - newser.com
How to use a screener to detect Aclaris Therapeutics Inc. breakoutsJuly 2025 Big Picture & Expert Curated Trade Setup Alerts - newser.com
Is Aclaris Therapeutics Inc. (8AT) stock a momentum leaderAnalyst Downgrade & Low Risk Profit Maximizing Plans - newser.com
What drives Aclaris Therapeutics Inc stock priceContrarian Investment Ideas & Investment Recommendations You Can Trust - earlytimes.in
Aclaris Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Will Aclaris Therapeutics Inc. (8AT) stock benefit from mergersQuarterly Performance Summary & Expert Curated Trade Ideas - newser.com
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 31% But Its Business Is Yet to Catch Up - 富途牛牛
Revenues Not Telling The Story For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Shares Rise 31% - simplywall.st
Aclaris Therapeutics’ ATI-045 Study: A Potential Game-Changer for Atopic Dermatitis - TipRanks
Will Aclaris Therapeutics Inc. stock outperform Dow Jones indexMarket Risk Analysis & Low Risk Investment Opportunities - newser.com
Aclaris Therapeutics Inc Stock (ACRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):